Bausch & Lomb has made an equity investment in AcuFocus.
Bausch & Lomb has made an equity investment in - and secures an exclusive option to purchase - AcuFocus, a privately held company in California, USA.
AcuFocus is developing a corneal inlay, the ACI 7000, for the treatment of presbyopia. The inlay is implanted in the cornea under a LASIK flap and incorporates technology that increases a patient's depth of field, thereby improving near vision. The procedure involves no tissue removal and does not permanently alter the cornea, so pre-implant vision can be restored should the inlay be removed. Terms of the agreement were not disclosed.
COPHy 2023: Restorative therapies and the path to them
March 24th 2023In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.
APAO 2023: Keralink Trial and efficacy safety of corneal cross-linking for children with Keratoconus
February 25th 2023The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.
2 Clarke Drive
Cranbury, NJ 08512